Researched by Belong.Life and published by ASCO
Data from the Belong PPN successfully captured the spectrum of PD-1 inhibitors’ reported AEs. Analyzing PRO of post approval treatments could provide deeper understanding of treatment patterns, expose limiting AE that bear implications on cost of treatment, indicate patients’ quality of life (QOL), improve management recommendations and provide a comprehensive outlook of patients’ outcomes.
Belong.Life is a global leader in digital health, revolutionizing the patient experience and delivering unparalleled value for patients, healthcare providers, pharmaceutical companies, and payers.
Belong’s key solutions include the world’s largest social and professional networks for people living with cancer (Belong – Beating Cancer Together) and multiple sclerosis (BelongMS), and the BelongAI health-grade patient engagement and support platforms including Dave AI Cancer Mentor medically validated by renowned oncologists at ASCO and ESMO, Sophie– AI MS Mentor, Tara – AI Clinical Trials Matching Assistant and Fred – AI Weight and Health Mentor, which utilizes AI to proactively support and empower patients throughout their healthcare journey.
